H295R (also referred to as NCI-H295R) is an angiotensin-II-responsive steroid-producing adrenocortical cell line.[1] It was initially isolated in 1980 from a 48-year-old female patient diagnosed with adrenocortical carcinoma.[1][2] The initial polyclonal populations of tumor cells obtained from the patients' tumor were cultured and the resultant cell line was called NCI-H295.[1][2] Because of slow growth rates and easy detachment of the original NCI-H295 strains, efforts were made to select a population of cells with better monolayer attachment and more rapid growth.[1] Three strains were developed, based on the serum supplement used for growth, which have been termed H295R-S1, H295R-S2 and H295R-S3.[1][3] All three strains grow as adherent monolayer cultures.[1]

References

  1. 1 2 3 4 5 6 Wang T, Rainey WE (2012). "Human Adrenocortical Carcinoma Cell Lines". Mol. Cell. Endocrinol. 351 (1): 58–65. doi:10.1016/j.mce.2011.08.041. PMC 3288152. PMID 21924324.
  2. 1 2 Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV (1990). "Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis". Cancer Res. 50 (17): 5488–5496. PMID 2386954.
  3. ↑ Rainey WE, Saner K, Schimmer BP (2004). "Adrenocortical cell lines". Mol. Cell. Endocrinol. 228 (1–2): 23–38. doi:10.1016/j.mce.2003.12.020. PMID 15541570. S2CID 1628345.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.